Sacituzumab govitEcan in THYroid Cancers

NCT06235216 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Differentiated Thyroid Cancer
Anaplastic Thyroid Cancer

Interventions

DRUG: Sacituzumab govitecan

Sponsor

Grupo Espanol de Tumores Neuroendocrinos

Collaborators

[object Object]
[object Object]